Literature DB >> 20416875

Animal models of traumatic brain injury: is there an optimal model to reproduce human brain injury in the laboratory?

M C Morganti-Kossmann1, E Yan, N Bye.   

Abstract

Compared to other neurological diseases, the research surrounding traumatic brain injury (TBI) has a more recent history. The establishment and use of animal models of TBI remains vital to understand the pathophysiology of this highly complex disease. Such models share the ultimate goals of reproducing patterns of tissue damage observed in humans (thus rendering them clinically relevant), reproducible and highly standardised to allow for the manipulation of individual variables, and to finally explore novel therapeutics for clinical translation. There is no doubt that the similarity of cellular and molecular events observed in human and rodent TBI has reinforced the use of small animals for research. When confronted with the choice of the experimental model it becomes clear that the ideal animal model does not exist. This limitation derives from the fact that most models mimic either focal or diffuse brain injury, whereas the clinical reality suggests that each patient has an individual form of TBI characterised by various combinations of focal and diffuse patterns of tissue damage. This is additionally complicated by the occurrence of secondary insults such as hypotension, hypoxia, ischaemia, extracranial injuries, modalities of traumatic events, age, gender and heterogeneity of medical treatments and pre-existing conditions. This brief review will describe the variety of TBI models available for laboratory research beginning from the most widely used rodent models of focal brain trauma, to complex large species such as the pig. In addition, the models mimicking diffuse brain damage will be discussed in relation to the early primate studies until the use of most common rodent models to elucidate the intriguing and less understood pathology of axonal dysfunction. The most recent establishment of in vitro paradigms has complemented the in vivo modelling studies offering a further cellular and molecular insight of this pathology. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20416875     DOI: 10.1016/j.injury.2010.03.032

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  35 in total

1.  Injury-induced regulation of steroidogenic gene expression in the cerebellum.

Authors:  Anahid Mirzatoni; Rory D Spence; Kevin C Naranjo; Colin J Saldanha; Barney A Schlinger
Journal:  J Neurotrauma       Date:  2010-10-06       Impact factor: 5.269

Review 2.  Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.

Authors:  Na'ama A Shein; Esther Shohami
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

Review 3.  Combination therapies for neurobehavioral and cognitive recovery after experimental traumatic brain injury: Is more better?

Authors:  Anthony E Kline; Jacob B Leary; Hannah L Radabaugh; Jeffrey P Cheng; Corina O Bondi
Journal:  Prog Neurobiol       Date:  2016-05-07       Impact factor: 11.685

Review 4.  Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation.

Authors:  Patricia B de la Tremblaye; Darik A O'Neil; Megan J LaPorte; Jeffrey P Cheng; Joshua A Beitchman; Theresa Currier Thomas; Corina O Bondi; Anthony E Kline
Journal:  Neurosci Biobehav Rev       Date:  2017-05-30       Impact factor: 8.989

5.  The acute phase of mild traumatic brain injury is characterized by a distance-dependent neuronal hypoactivity.

Authors:  Victoria P A Johnstone; Sandy R Shultz; Edwin B Yan; Terence J O'Brien; Ramesh Rajan
Journal:  J Neurotrauma       Date:  2014-09-11       Impact factor: 5.269

6.  Moderate traumatic brain injury triggers rapid necrotic death of immature neurons in the hippocampus.

Authors:  Hongzhen Zhou; Liang Chen; Xiang Gao; Bingde Luo; Jinhui Chen
Journal:  J Neuropathol Exp Neurol       Date:  2012-04       Impact factor: 3.685

7.  'Hit & Run' model of closed-skull traumatic brain injury (TBI) reveals complex patterns of post-traumatic AQP4 dysregulation.

Authors:  Zeguang Ren; Jeffrey J Iliff; Lijun Yang; Jiankai Yang; Xiaolin Chen; Michael J Chen; Rebecca N Giese; Baozhi Wang; Xuefang Shi; Maiken Nedergaard
Journal:  J Cereb Blood Flow Metab       Date:  2013-02-27       Impact factor: 6.200

8.  T-cell factor (TCF/LEF1) binding elements (TBEs) of FasL (Fas ligand or CD95 ligand) bind and cluster Fas (CD95) and form complexes with the TCF-4 and b-catenin transcription factors in vitro and in vivo which result in triggering cell death and/or cell activation.

Authors:  Xia Liu; Yuwei Huang; Yuanyuan Zhang; Xiaohong Li; Chun Liu; Shen Huang; Dezhi Xu; Yang Wu; Xiaojuan Liu
Journal:  Cell Mol Neurobiol       Date:  2016-04-18       Impact factor: 5.046

Review 9.  Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Authors:  Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer
Journal:  J Neurotrauma       Date:  2014-01-15       Impact factor: 5.269

10.  Analysis of functional pathways altered after mild traumatic brain injury.

Authors:  John B Redell; Anthony N Moore; Raymond J Grill; Daniel Johnson; Jing Zhao; Yin Liu; Pramod K Dash
Journal:  J Neurotrauma       Date:  2013-05-07       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.